- Zeria Pharmaceutical has launched Hanp Inj (carperitide) in Japan for the management of patients with acute heart failure. The drug is said to be the first recombinant alpha-type human atrial sodium diuretic polypeptide preparation to reach the market, according to Pharma Japan. Zeria is targeting first-year sales of 360 million yen ($4.3 million). The drug reportedly has arteriovenous vasodilating and diuretic effects, improves preload and afterload, does not cause an increase in heart rate or myocardial oxygen consumption and has a low incidence of side effects (5.1%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze